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Interactive Communication in Pharmacogenomics Innovations: 
User-producer interaction from an innovation and science 
communication perspective 
 




Pharmacogenomics is a quickly evolving field of research that increasingly impacts 
individuals and society. As some innovations in biotechnology have experienced 
strong public opposition during the 1990s, interaction between producers and users of 
these innovations may help in increasing their success in social and economic terms. 
However, conditions for effective interaction have so far remained under-explored. 
This paper explores user-producer interactions in pharmacogenomics from an 
innovation and science communication perspective in the Netherlands. To find 
possible ways of engaging stakeholders in an early stage of technology development, 
ie, when science policy is in the making, we present communication activities derived 
from the field of policy analysis. To articulate motives for two-way public 
participation in genomics innovation processes, we describe two levels at which 
pharmacogenomics developments will have an input:1) at the meso-level of medical 
practice with already established medical technologies, values and routines, suppliers 
and health professionals (general practitioners, pharmacists), and 2) at the macro-level 
of society at large, with established institutions, infrastructures, and broadly shared 
values and beliefs among citizens in general. Thereby we offer a starting point for 
optimising decision-making processes in the field of pharmacogenomics innovations, 
including important aims to be reached, stakeholders to be involved, and some criteria 




Pharmacogenomics is a relatively young and quickly evolving field of research, 
which promises to release a variety of new innovations in clinical practice and in 
everyday life. It is beginning to harvest the genetic information available after the 
completion of the Human Genome Project and convert it into functional innovations, 
eg, (pharmaco)genetic tests and tailored medicines for (groups of) patients and 
consumers. Pharmacogenomics is defined here as: 
 
“the study of the variability of the expression of individual genes 
relevant to disease susceptibility as well as drug response at 
cellular, tissue, individual or population level. The term is broadly 
applicable to drug design, discovery, and clinical development”2 
 
It implies genome-wide searches for genes and their products (ie, proteins) involved 
in (common) diseases and the provision of new targets for therapy. In addition, 
pharmacogenomics aims to identify genes involved in adverse reactions to drugs. 
Pharmacogenomics increases the potential for early diagnosis and fine-tuning of 
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prognoses for diseases of adulthood, eg, cancer, cardiovascular diseases, diabetes and 
neurodegenerative diseases, eg, Alzheimer’s disease. Some companies already 
provide individuals with their own genotypes and estimated associated risks deduced 
from clinical association studies. 
 
As some innovations in biotechnology have suffered from strong public opposition 
during the 1990s, interaction between the producers and users of these innovations 
has been suggested to be essential in increasing the success of these innovations in 
social and economic terms.3 User-producer interactions work both ways. Users can 
gain attention for their (future) needs and have influence on the research and 
development processes by which these needs may be fulfilled. Producers gain access 
to the potential creativity and tacit knowledge of users and improve the societal 
acceptance of (future) innovations. It has been claimed that user involvement also 
contributes to the democratic content of decision-making on innovation.4 However, 
the interaction process itself often remains a “black box”, and conditions for its 
optimization remain rather unclear.  
 
The influence of users in pharmacogenomics is ambiguous. Producers, within science 
and the science-based pharmaceutical industry, play a major role in the development 
of new drugs, and “users” (eg, patients, consumers, general practitioners) cannot be 
typified as a group of homogeneous mass-consumers. Furthermore, as 
pharmacogenomics is still an emerging technology in an embryonic phase of its 
development characterised by high uncertainties and need for flexibility, the 
Collingridge dilemma applies:5 in an early stage of an emerging technology it is 
difficult for stakeholders to specify their needs, visions, goals and ethical 
considerations. In later stages, when actors know better how they want to intervene, 
the options to do so are limited. Therefore it has been argued that users and other 
stakeholders should be supported in articulating their demands and participating in 
science and technology policy-making as early as possible.6 
 
This paper explores user-producer interaction from an innovation and science 
communication perspective. To find possible ways of engaging users and other 
stakeholders in early stage technology development, ie, when science policy is in the 
making, we present some activities of user-producer interaction derived from the field 
of policy analysis. The diversity of pharmacogenomics stakeholders and the different 
contexts in which pharmacogenomics innovations will be used arguably have 
implications for the manner of user-producer interaction. Therefore two levels are 
distinguished at which future pharmacogenomics innovations will have an input: the 
level of medical practice and of society at large, focussing on The Netherlands. The 
final part of this paper presents some implications for communication strategies in 
pharmacogenomics. 
 
User producer interaction 
 
An innovation perspective 
In innovation studies, the importance of including users in innovation processes has 
been widely acknowledged.7 These studies have shown that intensified user-producer 
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interaction increases the success of innovations. Presently, innovation processes are 
considered as dynamic, complex and interactive processes. The linear model of 
innovation, in which new technologies are transferred from scientists (discovery) to 
developers and producers (invention and innovation) to consumers (diffusion) in a 
one-way direction, does not reflect the mechanisms that operate in reality. Actual use 
of the innovative product during clinical trials is necessary to generate knowledge that 
is required to improve the product. In other words, innovation is very much a process 
of “learning by using” and “learning by doing”8 Innovations also emerge in close 
interaction with their (socio-economic) environment. Nelson and Winter9 
characterized this process as co-evolution with continuous feedback and feed 
forwards to align the redesign of product characteristics and user requirements. 
Accordingly, new technologies are developed in a dynamic and complex environment 
and are shaped in an interactive process in which several actors (users, producers, 
suppliers, public researcher organizations, etc.) are involved.10 Networks and inter-
organizational relationships are the arena in which the learning processes between 
producers and users take place.11 
 
In the pharmaceutical industry, innovation processes are organized in a highly 
regulated way. The drug development and approval process entails several stages of 
clinical trials after discovery and preclinical testing have been completed successfully. 
The pharmaceutical company is the most dominant player throughout all stages. 
Innovations are highly science-driven and user participation is mostly limited to 
patients’ and physicians’ partaking in clinical trials and the post-marketing stage. 
Current problems in pharmaceutical innovations include: the long time-span of drug 
development (and its related high costs); problems with side effects (and drug safety); 
restricted pools of potential drug targets; diminishing active compound success rates; 
diminishing numbers of drugs in the development pipeline, and; sales income as 
established drugs reach their end of patent cover. Novel approaches of 
pharmacogenomics are aimed at alleviating the long and expensive innovation 
process,12 allowing for the introduction of a more demand-oriented health care 
model.13 
 
In contrast to the “classical” pharmaceutical innovation model, patients/consumers are 
becoming more actively involved in decision-making processes.14 Patient 
organizations in general are positive about new technologies, have experiential 
knowledge related to their illness and wish to be involved in decision making. They 
have gained increasing influence in scientific agendas, either through their supply of 
financial support for research or by providing scientists with societal problems to 
address and by exerting political influence. For example, the Dutch Celiac Disease 
Consortium includes industry, universities and the patient community to develop safer 
foods and more effective diagnosis, prevention and treatment of Celiac disease.15 
 
However, research in the Netherlands shows that the vast majority of patient 
organizations are not lobbying actively when it comes to influencing medical research 
budgets or research agendas.16 Two main obstacles for patient participation have been 
demonstrated: the resistance of the current biomedical research decision-making 
regime towards change, and the limited capability of patients to participate in, and 
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contribute to, decision-making in this area.17 The UK has a long history of patient 
participation in biomedical research starting in the mid-19th century.18 Since 1996, the 
advisory group Consumers in National Health System Research (named INVOLVE 
since 2003) has advised the government on patient and public participation in medical 
research. Through their efforts the UK has an extensive network of patients, medical 
professionals and organizations who aim for public participation in research. The 
James Lind Alliance is such an organization where clinical researchers and patients 
meet to agree on relevant research questions, such as the effectiveness of a particular 
medical treatment. 
 
In the Netherlands there are some cases of patient participation, mostly in the area of 
orphan diseases (rare diseases). Within these orphan disease communities it is now 
more common practice to articulate demands, pass judgments on priorities for 
(public) research agendas, and channel information to companies or fellow patients.19 
After years of lobbying, the Dutch Genetic Alliance (VSOP), an umbrella 
organization of about sixty national, disease-linked, patient organisations, is 
increasingly involved in national and international policy-making on genetic 
research.20 Another example of an orphan disease community is the international 
Duchenne Parent Project, which was founded in the Netherlands in 1994. It has 
collected and spent more than three million euros on research on Duchenne muscular 
dystrophy at 13 different universities across Europe.21 Further examples of patient 
participation are shown in a case study on the Dutch Neuromuscular Disease 
Association (VSN), which focuses on patient involvement in emerging and more 
established therapies such as gene therapy for Pompe and Duchenne disease, stem cell 
therapy for Amyotrophic Lateral Sclerosis (ALS) and Enzyme Replacement Therapy 
for Pompe Disease.22 
 
The discovery of many low-penetrance/high-frequency genes correlated with health 
risk challenges concepts of healthy and sick, because genetically there is no clear 
distinction between health and disease. A high proportion of the general population 
are carriers of at-risk genotypes,23 so patients are not the only (potential) users of 
genomics innovations. To pharmaceutical companies phenotypically healthy people 
become genotypic “protopatients” for which preventive strategies could be developed, 
such as genetic tests to anticipate future illness that is encoded in their genes. 
Technological innovations make gene sequencing ever faster and cheaper, which 
makes it possible to offer test facilities on a commercial basis. Commercial 
enterprises enter the market with direct-to-consumer products such as genetic tests, 
increasingly via internet,24 and many more offer preventive DNA tests to the public at 
large. The regulation concerning these tests is often much less strict than regulation 
about medication.25 
 
Consequently, since pharmacogenomics innovations are also intended for future 
patients, possible “users” include healthy citizens as well. Hence, to increase the 
social robustness of genomics research and to realise the potential of new genomics 
innovations arising from it, we need to address the social, ethical and legal issues in 
an ongoing dialogue with a broader group of stakeholders. Since agricultural and food 
biotechnology has faced a negative image for some time now, especially in the EU, 
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although its medical applications have been generally welcomed especially by 
patient’s organisations, and since the term “biotechnology” may not be differentiated 
in many people’s minds, new types of interaction are required. The Netherlands 
Genomics Initiative (NGI), which coordinates genomics research in the Netherlands 
(NGI), states in this matter:26 
 
“If we really want to realise the potential of genomics we shouldn’t 
back away from difficult topics, but approach fears and concerns 
with an open mind. Only then will we lay the foundations for the 
necessary social trust in genomics.” 
 
Fostering synergy between progress in science and its application in society is a major 
challenge in science communication, and requires not only public understanding of 
science and awareness of its new implications, but public participation in science 
policy as well. Patients, their representatives, physicians, pharmacists and insurance 
companies, and indeed the public at large representing “future patients”, are important 
stakeholders in genomics developments. However, their role in the decision-making 
processes regarding new genomics technologies has not been very profound yet.  
 
User-producer interaction: Public Participation in Science? 
In the Netherlands, a total budget of 280 million euros is allocated to new genomics 
research for the period 2008-2012.27 25 Million euros of that has been allocated to 
societal research, public communication and education concerning genomics. In this 
way, the Netherlands Genomics Initiative (NGI) aims to contribute to a more 
balanced and informed public debate in which stakeholders hopefully together decide 
which genomics developments are needed and desirable.  
 
The reciprocal nature of the communication aims, as explicated by the NGI,28 is in 
line with recent views on science communication. In the 1990s authors including 
Brian Wynne29 and John Durant30 discussed the idea of a paradigm shift in science 
communication. Several reasons were provided for the need for such a change, often 
based on the desirability of scientific progress and expressed as a need to increase 
acceptance or trust in science and technology.31 It was suggested that science 
communication should be less limited to mass-media and should make more use of 
interpersonal and other more interactive forms of communication. Since then, various 
scholars have provided evidence for an observed shift from a transmission model of 
communication to a more interactive or participative approach involving the public in 
decision-making on scientific and technological developments.32 
 
The gradual changes from monologue to dialogue can be observed through the use of 
different notions in science communication literature.33 Public understanding of 
science (PUS) built on the idea that people would more readily accept new technology 
and products when they understood the science behind it. Methods were merely based 
on traditional, one-way dissemination of information to the lay public. In this 
transmission or so-called “deficit model” the public is seen as a passive and 
monolithic mass, whose scientific literacy should be increased in order to achieve 
greater support for science and its financing.34 
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In the subsequent movement of Public Awareness of Science (PAS) the public is 
given a more active role in the communication process. PAS aims to make people 
aware of the impact (costs and benefits) science can have on society. This necessitates 
an active process in the receiver contributing to the cost-benefit analysis, and hence 
more two-directional communication processes are suggested recognising that each 
audience has specific knowledge, experiences and needs. 
 
Public Engagement of Science (PES) further increases the role of the receiver 
responding to the (social) scientific debate on the notion of knowledge as a social 
construct.35 The latter implies that scientific progress is the result of a continuous 
interaction process, in which many stakeholders are involved. Accordingly, science 
communication should be seen as a means to optimize this mutual interaction or 
engagement in science. In this view, communication is a transaction process in which 
scientific as well as ethical and social considerations are taken into account. The role 
of the public however remains restricted to consultancy for decision-making about the 
research agenda. The activities described for this (PES) process, such as surveys, 
citizen juries or referenda, often reflect the limited influence on the decision-making 
process.36 In the interaction between science experts and “non experts”, scientists still 
play a dominant role in the agenda-setting. In search of a more profound role for 
citizens, an increasing tendency towards participation of scientists and lay experts as 
equal partners in the communication process can be observed in both the literature 
and governance reports.37 Transparency has now been identified as a major criterion 
for trust. The aim of Public Participation in Science (PPS) is therefore ascribed to 
improving the transparency and democratic quality of decision-making processes on 
the choice of scientific research, and is aimed at improving the quality of life in 
society. In a way, public participation presupposes a certain level of public 
understanding and awareness, so the experiences gained in activities focussed on 
these aims are all relevant for the goals of PPS.  
 
However, as we argued in the previous section, in the Netherlands, important users of 
genomics developments, such as patients, physicians and healthy citizens, are not 
structurally involved in decision-making about new genetic technologies. Wynne38 
argues that this non-involvement of citizens is structural in practice, as institutions 
continually reinvent public-deficit explanations to prevent the technological 
development process from being debated publicly. In addition to this observed lack of 
action from the institutional side, we cannot take for granted that future users or even 
the majority of current users are keen to take part in “scientific decision making” and 
are entirely capable of doing so. In conclusion, we need better forms of interaction, 
and this is not going to be easy. 
 
The Dutch Council for Social Development (RMO, The Hague, Netherlands) also 
concludes that, in the societal debate on human genetics, the medical-genetic 
discourse is still very dominant. The council strongly recommends that this debate be 
supplemented with “social participative discourse”, and that more emphasis be given 
to the consequences of human genetics developments in terms of quality of life.39 
This means that public questions and concerns over modes of innovation, eg, the 
hyping of promises of social benefits, should be taken seriously as well. 
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Communication then moves from the genomics-content knowledge to issues related 
to risk perception, regulation and ethics and involves emotions, including anxieties.40 
The key question remains, however, as to how we should, and can, shape 
communication in order to contribute to informed users and producers benefiting from 
each others’ expertise and finding common ground to make decisions for the 
development of new genomics innovations. The next section outlines a 
conceptualization of such two-way communication in emerging innovations, based on 
theories in policy analysis. 
 
Towards two-way communication in pharmacogenomics  
For insight into ways of facilitating close interaction and knowledge integration 
between stakeholders, we could learn from fields where participatory approaches have 
been implemented. As such a field, policy analysis offers valuable reflections on the 
relationship between applied research and the use and development of methods in 
relation to policy or decision-making processes. As policy analysis is a multi-faced 
field in which a variety of different activities, approaches and methods have found a 
place, we draw on a conceptual framework developed by Mayer et al.41 This 
framework offers an overview of the activities and styles that claim to make up policy 
analysis and has been developed as a contribution to the development of interactive or 
participatory methods and guidance for evaluating such methods. Their analysis 
covers 20 exemplary cases related to technological decision- and policy-making in the 
Netherlands. Two of the selected projects concern genetic and medical technology: 
consensus conferences on genetic modification and a systemic review of disease-
modifying anti-rheumatic drugs-therapy in rheumatoid arthritis.  
 
In their classification of activities, roles and values in decision- making processes, 
two interaction styles explicitly focused on gathering input from scientists, medical 
professionals and citizens: the interactive style and the participatory style.42 The 
interactive style primarily focuses on gaining insight in different views and achieving 
mutual understanding. It implies the invitation of different stakeholders to structure 
problems or devise solutions in structured work meetings at which diverse interactive 
techniques may be used. It mainly focuses on mediation and democratising activities. 
The participants learn about their own views in relation to those of others, and have 
an opportunity to refine these. What matters is the quality of the insights obtained in 
combination with the heterogeneity of opinions and interests. Users can be consulted 
in workshops about problems they experience and the wishes and concerns they have 
regarding certain new genomics innovations. This way the process aims to improve 
the acceptance and adaptation of (future) innovations, and facilitates participants to 
learn from each other. For example, producers get insight into the daily context in 
which their product is used. 
 
The participatory style aims at improving the democratic quality of decisions relevant 
for society and combines democratising activities with clarifying values and 
arguments.43 It assumes that citizens have a voice and are, or become, interested 
enough to deliberate on substantive and politically difficult questions. Equality and 
openness should be promoted in communication activities by giving laymen a role 
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alongside other stakeholders. These are important characteristics for attaining public 
trust and transparency in science and technology. 
 
Both styles of decision-making comprise three dominant communication activities: 1) 
clarifying values and arguments, 2) democratization, and 3) mediation. Clarifying 
values and arguments aims to bring implicit normative and ethical issues behind 
public policy to the surface. In the field of pharmacogenomics, clarifying values, 
interests and (emotional) arguments of scientists, medical professionals and 
patients/citizens is an important analytical step for reaching common ground and 
“shared decision making”. The inclusion of lay public actors in defining the issue at 
stake prevents a technological framing of the issue and increases the interest and 
commitment of citizens to take part in “scientific decision making”. Democratization 
focuses on the improvement of citizens’ abilities to make an informed choice and 
have influence on decisions of new genomics technologies. It should empower all 
relevant stakeholders, including industrial platforms and patient advocacy groups to 
engage in decision-making processes. Mediation activities are helpful in innovation 
processes when building trust between actors from different communities of practice 
is central. It aims at sharing perspectives between stakeholders, and enabling learning 
processes during which the (scientific) knowledge-gap between experts and laymen 
can be bridged. This step seems essential as the field of pharmacogenomics implies 
rather complex issues playing a role in future expectations about an emerging 
technology. 
 
The next section elaborates some examples of two-way communication processes 
between users and producers of pharmacogenomics developments at the level of the 
medical practice and for society at large.  
 
Pharmacogenomics communication processes in medical practice and society at 
large  
 
As we have argued, user-producer interaction in pharmacogenomics implies 
participation of key users, ie, physicians, patients and the public at large, in decision-
making regarding new innovations. To point out relevant activities and specific users 
that should be included in such decision-making processes, we will distinguish two 
levels at which pharmacogenomics developments will have an input: 1) the meso-
level of medical practice with already established medical technologies, practices, 
values and routines, suppliers and health professionals (general practitioners, 
pharmacists), patients and patient organisations and; 2) the macro-level of society at 
large, with established institutions, infrastructure, and broadly shared values and 
beliefs among citizens in general.44 
 
The medical practice and the rise of pharmacogenomics 
Many promises of pharmacogenomics are still speculative and revolve around its 
effect on future medical practice and everyday life. The Royal Society45 has 
summarized some main ethical and societal concerns, based on several bioethics 
reports. Their report concludes that health professionals such as General Practitioners 
(GPs) are important actors in the pharmacogenomics era, who need to be trained in 
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communicating pharmacogenetic information and the associated risks to individual 
patients.46 Screening, counselling and referring patients are important tasks for these 
primary healthcare professionals which can ensure incorporation of genomic medicine 
into primary care. From a public perspective, GPs are also important actors as they 
are regarded by the Dutch public as one of the most trustworthy professions, when 
compared to scientists, politicians and journalists.47 However, their capacity to keep 
their knowledge sufficiently up to date and their ability to support patient choice is 
questioned.48 Research underlines these concerns. Suther and Goodson49 suggested 
that genomics services do not easily fit into the current practice of GPs, and in the 
Netherlands GP’s have been shown to have insufficient knowledge of genetics.50 
 
Only few studies have examined primary care practitioners’ (including GPs’) beliefs 
regarding genetics and the incorporation of genomic medicine into practice. Given 
this dearth of empirical data, Suther and Goodson51 provided some insight in whether 
and to what extent primary care practitioners’ perceptions of genetic medicine as an 
innovation influence their likelihood of adopting this innovation into primary care. 
Despite the anticipated advantages and consistency of genomic medicine with 
professional practice, the complex nature of genomics tasks seems to reduce their 
implementation. More than half (54.3%) of the primary care practitioners believed 
that staying updated on genomic-related knowledge is (extremely) difficult.52 
Moreover, tasks such as ordering genetic testing and providing genetic counselling do 
not fit easily into their current practice. In line with other studies, lack of time and 
knowledge about genetic counselling seem important barriers for the provision of 
genetic services in primary care. These findings indicate that although professionals 
in primary care are most willing to adopt genomic medicine into their practice and 
strongly believe that it provides important advantages above traditional forms of 
medical practice, very few physicians already provide specific genetic services to 
their clients. Lack of time and knowledge about the complex genomics tasks seem to 
be important barriers to adoption. 
 
To bridge the gulf between health-care practitioners and pharmacogenomics 
producers, the latter should not suffice with one-way communication (PUS) 
concerning their new products. Given the influence of the barriers to implementation, 
and the important role of primary care practitioners in the adoption of genomics 
medicine in primary care, they should participate early in the innovation process. 
Physicians are generally open to the advantages of genomics medicine, and input of 
their professional experience could improve the compatibility of genomics medicine 
with professional practice. On the other hand, more focus should be placed on 
enabling GPs and health-care professionals in general to understand and utilize 
genetic-based probability and risk assessment, and to communicate effectively about 
them. Health-care professionals in general are not well prepared to deal with genetic 
information,53 but they have an essential role in empowering their patients (or their 
phenotypically healthy customers) for personal decision-making, based on genetic 
information. As Guttmacher et al argue,54 three aspects are of main importance: the 
role of family history to determine the mode of inheritance; awareness of the 
individual information that genetic tests might give and; making appropriate referrals 
to a genetic specialist. 
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Society at large and the rise of pharmacogenomics 
At the societal level, demand-oriented health care relates to the trend towards the 
active involvement of the patient or consumer in decision-making processes. Within 
the field of pharmacogenomics, medicines may be customised to the genetic 
constitution of groups of patients. As a result, the role of patient-advocacy groups will 
increase in the process of demand-articulation in a more segmented market. Also, 
increasing access for patients to information via the Internet is resulting in higher and 
more specific demands. However, so far we have argued that public participation in 
emerging technological developments is not yet very common and a novel yet 



























Figure 1: Potential users of pharmacogenomics innovations in different contexts ranging 
from restricted use in medical practice (top) to free availability in society at large (bottom). 
 
 
Figure 1 gives an impression of the different contexts in which genomics innovations 
will likely be used, with some appointed intermediate and end users. The use of 
genomics innovations will vary from restricted use in hospitals under the supervision 
of specialists to products freely available on the market. The Internet already plays a 
crucial role in selling products such as direct-to-consumer (genetic) tests and as a 
source of information about diagnoses and treatments together with their relative 
efficacy. Restricted use in hospitals involves obtaining informed consent from the 
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the interaction is not truly conducive to real informed consent, but the professional is 
required to attempt to assure that the patient really understands the choices and is not 
coerced. For food or chemical products, informed consent does not exist, as it is 
generally assumed that if the consumer purchases a product it is with consent unless 
and until something goes wrong. The two very different relationships are at both ends 
of the scale depicted in figure 1. 
 
“Use” pertains not only to the act of consume or taking in (in the sense of swallowing 
a pill), but also to the act of “deciding” to exploit an innovation’s possibilities: in the 
case of pharmacogenomics, pharmacists and physicians both play a role in deciding 
whether patients should be screened or treated for a certain disease. Within this 
context intermediate “users” make use of the opportunities of new innovations (eg, 
screening for a disease or ensuring a safer and more efficient therapy). 
 
Perception, value formation and the exchange of expectations are crucial factors in 
communication about new technologies. The rapid expansion of genomics research, 
and especially its applications in health care and nutrition, and its impact on the lives 
of people and society as a whole requires the ongoing involvement of all stakeholders, 
including the general public, consumers, patients, health-care professionals, policy 
makers, etc. All these potential users should be empowered to make reasoned 
decisions regarding the integration of genomics innovations into their daily lives. 
Individuals or communities should therefore gain the ability to deal with the 
upcoming field of genomics (eg, articulate demands, needs or restrictions). At the 
level of society at large, criticism of new genomics developments often comes from 
broader, non-patient, societal organisations, such as pro-life, environmentalist and 
animal-rights groups, as they are better publicists than patient organisations and 
thereby gain better media and political attention, and hence influence.55 Nevertheless, 
Boon has found that intermediary user organisations, such as patient organizations (ie, 
Dutch VSN, Dutch Genetic Alliance VSOP), can be important loci of demand 
articulation. Such organisations influence the pharmacogenomics innovation process 
in several ways: overcoming market failures by articulating demands neglected by 
other actors; setting up scientific networks and constructing visions of the future; 
managing expectations and giving assistance in clinical trials, reimbursement and 
regulatory issues; addressing ethical and societal issues; and, ensuring the 
democratization of their demands by properly representing the (end) users.  
 
Following from the above, we could argue that in the range from Public 
Understanding of Science to Public Participation in Science, public communication in 
pharmacogenomics innovations could in general be typified as Public Engagement in 
Science. Intermediary user organisations are engaged in influencing the boundary 
conditions of pharmacogenomics innovations, and the broadening and enriching of 
debates. Sometimes, they have influence on R&D agenda-setting, but this is still less 
common.56 For a more participatory approach to user-producer interaction, actors in 
industrial, clinical and everyday life practices should be supported to specify their 
needs, goals and moral and ethical concerns in an early stage of emerging 
technologies. Clarifying the values behind these needs and concerns could stimulate 
finding common ground for ‘democratic’ decision-making processes regarding new 
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genomics innovations in which both ‘certified experts’ and non-certified or public 
experts can have equal input. Indeed, research on public surveys suggests a need for 
further analyzing moral and ethical components of science communication.57 For 
example a special Eurobarometer report 225, entitled ‘Social values, Science and 
Technology’,58 showed that although half of the European respondents said that 
decisions on science and technology should be based on an analysis of the risks and 
benefits of certain technology, a substantial group (41 %) thought that moral and 
ethical dilemma’s should have priority when decisions are made.  
 
Concluding remarks and implications for interactive user-producer 
communication 
 
Besides the political argument that participation of users in science improves its 
legitimacy and chances for successful implementation, users are an important source 
of tacit knowledge for producers. Users can develop new functions for technologies, 
solve unforeseen problems and propose or even develop innovative solutions. In a 
rapid expanding field of pharmacogenomics it is difficult for stakeholders to specify 
their needs, visions, goals and ethical considerations. Therefore users, including the 
general public, consumers, patients, health-care professionals and policy makers 
should be supported to articulate their demands and to participate in science and 
technology policy making as early as possible. Up till now in the Netherlands, 
important users of genomics developments such as patients, physicians and healthy 
citizens have not structurally been involved in decision-making on new genetic 
technologies.  
 
This paper has articulated user-producer interaction in pharmacogenomics 
innovations at the level of the medical practice and at the broader societal level. To 
medical practices, pharmacogenomics will have increasing implications, but new 
innovations do not fit easily in daily routines of medical professionals. For genomics 
to effectively change the medical practice, advances in the genetic literacy of (non-
geneticist) health professionals59 need to be made. Within medical practice, decisions 
have to be made regarding the development and use of new genomics-based 
applications e.g. a diagnostic test or personalized medicine. Mutual understanding and 
commitment of key users, i.e. of primary care practitioners or GP’s, and producers, ie, 
pharmaceutical companies and scientific researchers concerning a specific innovation 
and the conditions for implementation should be the basis for these decisions. New 
participatory approaches for decision making in medicine fit into the new 
developments in evidence-based medicine (EBM) and could start from existing 
guideline development groups. EBM is a systemic approach to clinical problem 
solving which combines research evidence, clinical expertise and the patient 
perspective.60 The Dutch Mamma Carcinoma Guideline is an example of a ‘living’ 
guideline which is continually being updated based on interaction between members 
of the Dutch Breast Cancer Association (BVN) and several medical associations. 
Although in guideline development research evidence is still dominant, physicians 
and patients are participating to improve the implementation of a genomics innovation 
so that it will fit in their daily routines.  
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Within the society at large, different contexts of use (see figure 1) imply that different 
user groups exist in pharmacogenomics innovation processes: the majority, i.e. mass 
consumers of free available products who are at best marginally interested in 
genomics technology and the minority, i.e. patients and medical professionals who are 
interested and motivated to participate in decision making processes regarding their 
illness.  
 
As Caron-Flinterman61 has shown in the Netherlands, patients are hardly involved in 
biomedical decision-making processes because of their presumed lack of competence. 
To engage the minority in decision-making processes on pharmacogenomics 
innovations, Dutch patient organisations should play a more active role. They could 
inform patients in a scientifically sound way about new genomics technologies, 
including efficacy and safety issues as patients are mostly ignoring these issues while 
they are in favour of innovative medicines that could possible cure them. 
Furthermore, patient organisations often negotiate, shape and communicate the social, 
legal and ethical impacts of a new technology. They play an intermediary role 
between patients and genomics developers (mediation), clarifying scientific 
arguments and translating patients’ needs and values. One way of increasing patients 
influence on research agenda’s is raising money and allocating this to research 
proposals. To increase patient participation in decisions on breast cancer research for 
example, the Susan Komen Fund in the United States already requires research 
proposals to be transcribed into a lay-version.  
 
In contrast to direct stakeholders, the ‘majority’ is far less easy to be reached and 
motivated to participate in decision-making processes. As the emerging field of 
pharmacogenomics implies rather complex issues playing a role in future 
expectations, it is questionable whether lay people are really that interested and 
knowledgeable about the issue. As Wynne62 has argued, raising people’s interest in 
deliberating on substantive and politically difficult questions requests a socially and 
ethically informed debate about the relations between scientific knowledge and other 
forms of knowledge and experiences, for example with respect to health care or 
problems encountered in everyday life.63 Such a debate should provide a consistent 
and rich notion of pharmacogenomics in society, based on specified needs, goals and 
moral and ethical concerns of a broad group of stakeholders. To guarantee the 
democratic quality and societal relevance of the eventual decisions attention should be 
paid to transparency and equal access of genomics experts and (non expert) citizens in 
discussion platforms, for example in a consensus conference format. As patient 
organisations mainly focus on management of their ‘own disease’, the representation 
of ‘healthy citizens’ in the debate deserves attention. In the Netherlands the Dutch 
Genetic Alliance (VSOP) is an important intermediary between health care users and 
producers. As an umbrella organisation of 60 parent and patient organisations, they 
represent a broader group of societal stakeholders and have developed a broad vision 
on the field of community genetics and genomics. From a democratic perspective they 
actively fight for integration of experiences and dilemma’s of healthcare users in the 
allocation of research funds. 
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In this article we have given a general outline of important aspects that should be 
considered in shaping public participation in pharmacogenomics innovations. To 
optimise the social and economic success of pharmacogenomics innovations, user 
groups such as general practitioners and patient organisations should be invited to 
engage in structured mediation activities to structure problems encountered in medical 
practice or daily life and or devise solutions. To bridge the gulf between producers 
and (end-)users, we suggest that assessments on (expectations of) pharmacogenomics 
developments should be organized as ongoing processes involving multiple 
stakeholders in order to search for solutions when the articulation of the potential of 
pharmacogenomics in society at large is coupled with institutionalization, i.e. when 
heterogeneous stakeholders discuss and influence the practice and emerging future of 
pharmacogenomics in forums.64 Forums are more than communication platforms, 
they can be spaces ‘specifically designed for pre-political deliberation or other 
interaction between heterogeneous actors with the purpose of informing and 
conditioning the form and direction of strategic social choices in the governance of 
science and technology’.65 
 
Structurally, these can be organised in very different ways, from very informal but 
persistent networks, to highly institutionalised bodies with a clear legal organisation 
and differentiated sub-structure.66 In the Netherlands, the Forum Biotechnology and 
Genetics (FBG) plays a role in policy consultation on biotechnology, genetics and 
health. Such a forum would not only be a multi-stakeholder form of governance but 
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